BR112018074716A2 - conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose - Google Patents
conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicoseInfo
- Publication number
- BR112018074716A2 BR112018074716A2 BR112018074716-5A BR112018074716A BR112018074716A2 BR 112018074716 A2 BR112018074716 A2 BR 112018074716A2 BR 112018074716 A BR112018074716 A BR 112018074716A BR 112018074716 A2 BR112018074716 A2 BR 112018074716A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical agent
- binding
- conjugates
- moiety capable
- sensitive protein
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
- 239000008103 glucose Substances 0.000 title abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000002441 reversible effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305640 | 2016-06-02 | ||
| EP16305640.1 | 2016-06-02 | ||
| PCT/EP2017/063447 WO2017207754A1 (en) | 2016-06-02 | 2017-06-02 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018074716A2 true BR112018074716A2 (pt) | 2019-03-12 |
Family
ID=56121007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074716-5A BR112018074716A2 (pt) | 2016-06-02 | 2017-06-02 | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11090364B2 (enExample) |
| EP (1) | EP3463480A1 (enExample) |
| JP (1) | JP2019520342A (enExample) |
| KR (1) | KR20190015413A (enExample) |
| CN (1) | CN109562185A (enExample) |
| AU (1) | AU2017272862A1 (enExample) |
| BR (1) | BR112018074716A2 (enExample) |
| CA (1) | CA3025988A1 (enExample) |
| IL (1) | IL263390A (enExample) |
| MX (1) | MX2018014929A (enExample) |
| RU (1) | RU2018147235A (enExample) |
| SG (1) | SG11201810701XA (enExample) |
| WO (1) | WO2017207754A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3025988A1 (en) * | 2016-06-02 | 2017-12-07 | Sanofi | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
| CN111433193A (zh) | 2017-12-01 | 2020-07-17 | 赛诺菲 | 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物 |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| CN115920081B (zh) * | 2022-11-02 | 2024-07-19 | 重庆大学 | 红细胞膜自发定向包被ros响应的纳米前药及其应用 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
| JP2003535106A (ja) | 2000-06-02 | 2003-11-25 | ノボ ノルディスク アクティーゼルスカブ | グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出 |
| EP1453860A2 (en) | 2001-12-02 | 2004-09-08 | Novo Nordisk A/S | Novel glucose-dependant insulins |
| JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
| FR2929615B1 (fr) | 2008-04-02 | 2010-12-17 | Tfchem | Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. |
| CN101638423B (zh) | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 根皮苷衍生物及其制备方法和用途 |
| US20110230403A1 (en) | 2008-09-19 | 2011-09-22 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2010088300A1 (en) * | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Crystalline insulin-conjugates |
| BRPI1007457A2 (pt) * | 2009-01-28 | 2015-08-25 | Smartcells Inc | Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba. |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| CA2794266C (en) * | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
| AU2011282977A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| WO2013121296A1 (en) | 2012-02-15 | 2013-08-22 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| JP2014510782A (ja) | 2011-04-14 | 2014-05-01 | ノバルティス アーゲー | グリコシド誘導体およびその使用 |
| PL2721045T3 (pl) | 2011-06-20 | 2017-11-30 | Radiomedix Inc. | Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych |
| KR20140145148A (ko) | 2012-03-21 | 2014-12-22 | 에리테끄 파르마 | 급성 골수성 백혈병 치료를 위한 약제 |
| WO2013182612A1 (en) * | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| KR20160065930A (ko) | 2013-10-04 | 2016-06-09 | 머크 샤프 앤드 돔 코포레이션 | 글루코스-반응성 인슐린 접합체 |
| ES2742102T3 (es) | 2014-01-15 | 2020-02-13 | Baseclick Gmbh | Moléculas de ácido nucleico modificadas con sacárido |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| WO2017124102A1 (en) * | 2016-01-14 | 2017-07-20 | North Carolina State University | Glucose responsive insulin delivery compositions and methods |
| CA3025988A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
-
2017
- 2017-06-02 CA CA3025988A patent/CA3025988A1/en not_active Abandoned
- 2017-06-02 AU AU2017272862A patent/AU2017272862A1/en not_active Abandoned
- 2017-06-02 CN CN201780047924.9A patent/CN109562185A/zh active Pending
- 2017-06-02 BR BR112018074716-5A patent/BR112018074716A2/pt not_active Application Discontinuation
- 2017-06-02 WO PCT/EP2017/063447 patent/WO2017207754A1/en not_active Ceased
- 2017-06-02 KR KR1020187038181A patent/KR20190015413A/ko not_active Ceased
- 2017-06-02 EP EP17730714.7A patent/EP3463480A1/en not_active Withdrawn
- 2017-06-02 RU RU2018147235A patent/RU2018147235A/ru not_active Application Discontinuation
- 2017-06-02 US US16/306,243 patent/US11090364B2/en active Active
- 2017-06-02 JP JP2018563040A patent/JP2019520342A/ja not_active Ceased
- 2017-06-02 MX MX2018014929A patent/MX2018014929A/es unknown
- 2017-06-02 SG SG11201810701XA patent/SG11201810701XA/en unknown
-
2018
- 2018-11-29 IL IL263390A patent/IL263390A/en unknown
-
2021
- 2021-06-23 US US17/356,294 patent/US20210401946A1/en not_active Abandoned
- 2021-06-23 US US17/356,339 patent/US20210401947A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017207754A1 (en) | 2017-12-07 |
| CA3025988A1 (en) | 2017-12-07 |
| SG11201810701XA (en) | 2018-12-28 |
| AU2017272862A1 (en) | 2019-01-17 |
| RU2018147235A (ru) | 2020-07-10 |
| US20210401947A1 (en) | 2021-12-30 |
| KR20190015413A (ko) | 2019-02-13 |
| IL263390A (en) | 2018-12-31 |
| US11090364B2 (en) | 2021-08-17 |
| JP2019520342A (ja) | 2019-07-18 |
| US20190209656A1 (en) | 2019-07-11 |
| MX2018014929A (es) | 2019-08-26 |
| US20210401946A1 (en) | 2021-12-30 |
| CN109562185A (zh) | 2019-04-02 |
| EP3463480A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41265B1 (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
| CL2018002699A1 (es) | Profármacos de fármacos citotóxicos que tienen grupos enzimáticamente escindibles. | |
| BR112018074716A2 (pt) | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose | |
| BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
| CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| SMP201600230A1 (it) | Composizione cosmetica | |
| CY1123574T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων | |
| BR112021022514A2 (pt) | Conjugados de anticorpo e fármaco | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| BR112016019592A8 (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| DK3870234T3 (da) | Antistoflægemiddelkonjugater omfattende ecteinascidinderivater | |
| MX379267B (es) | Composiciones de insulina de rapida accion. | |
| EP3723789A4 (en) | IDENTIFICATION OF LYSINES AND THEIR DERIVATIVES WITH BACTERIAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA | |
| IL283539A (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| DK3873600T3 (da) | Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelse deraf | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| DK3409660T3 (da) | Cyklisk aminderivat og farmaceutisk anvendelse deraf | |
| BR112017012337A2 (pt) | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. | |
| MX2018007231A (es) | Una composicion antimicrobiana. | |
| BR112014032764A2 (pt) | composição farmacêutica contendo fimasartana e hidroclorotiazida | |
| EP3328368A4 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITION RELATING TO THE UBIQUITINATION PROTEASOM SYSTEM | |
| EP3868371A4 (en) | Novel pharmaceutical composition | |
| EP3583943A4 (en) | PHARMACEUTICAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |